<?xml version='1.0' encoding='utf-8'?>
<document id="25047407"><sentence text="Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults."><entity charOffset="80-91" id="DDI-PubMed.25047407.s1.e0" text="armodafinil" /><entity charOffset="96-107" id="DDI-PubMed.25047407.s1.e1" text="ziprasidone" /><pair ddi="false" e1="DDI-PubMed.25047407.s1.e0" e2="DDI-PubMed.25047407.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25047407.s1.e0" e2="DDI-PubMed.25047407.s1.e1" /></sentence><sentence text="Armodafinil has been studied as adjunctive therapy for major depressive episodes associated with bipolar I disorder"><entity charOffset="0-11" id="DDI-PubMed.25047407.s2.e0" text="Armodafinil" /></sentence><sentence text=" This open-label, single-centre, 2-period study evaluated the effect of armodafinil, a moderate inducer of cytochrome-P450 (CYP) isoenzyme CYP3A4, on the pharmacokinetics and safety of ziprasidone, an atypical antipsychotic used to treat bipolar I disorder and metabolized in part by CYP3A4"><entity charOffset="72-83" id="DDI-PubMed.25047407.s3.e0" text="armodafinil" /><entity charOffset="185-196" id="DDI-PubMed.25047407.s3.e1" text="ziprasidone" /><pair ddi="false" e1="DDI-PubMed.25047407.s3.e0" e2="DDI-PubMed.25047407.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25047407.s3.e0" e2="DDI-PubMed.25047407.s3.e1" /></sentence><sentence text="" /><sentence text="Thirty-five healthy subjects received ziprasidone (20 mg) alone and after armodafinil pretreatment (titrated to 250 mg/day); of those, 25 were evaluable for pharmacokinetics"><entity charOffset="38-49" id="DDI-PubMed.25047407.s5.e0" text="ziprasidone" /><entity charOffset="74-85" id="DDI-PubMed.25047407.s5.e1" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.25047407.s5.e0" e2="DDI-PubMed.25047407.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25047407.s5.e0" e2="DDI-PubMed.25047407.s5.e1" /></sentence><sentence text=" Pharmacokinetic parameters were derived from plasma concentrations of ziprasidone collected prior to and over the 48 h after each ziprasidone administration"><entity charOffset="71-82" id="DDI-PubMed.25047407.s6.e0" text="ziprasidone" /><entity charOffset="131-142" id="DDI-PubMed.25047407.s6.e1" text="ziprasidone" /><pair ddi="false" e1="DDI-PubMed.25047407.s6.e0" e2="DDI-PubMed.25047407.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25047407.s6.e0" e2="DDI-PubMed.25047407.s6.e1" /></sentence><sentence text=" Plasma concentrations of armodafinil and its circulating metabolites, R-modafinil acid and modafinil sulfone, were also obtained after repeated daily dosing of armodafinil alone"><entity charOffset="26-37" id="DDI-PubMed.25047407.s7.e0" text="armodafinil" /><entity charOffset="71-87" id="DDI-PubMed.25047407.s7.e1" text="R-modafinil acid" /><entity charOffset="92-109" id="DDI-PubMed.25047407.s7.e2" text="modafinil sulfone" /><entity charOffset="161-172" id="DDI-PubMed.25047407.s7.e3" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.25047407.s7.e0" e2="DDI-PubMed.25047407.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25047407.s7.e0" e2="DDI-PubMed.25047407.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25047407.s7.e0" e2="DDI-PubMed.25047407.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25047407.s7.e0" e2="DDI-PubMed.25047407.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25047407.s7.e1" e2="DDI-PubMed.25047407.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25047407.s7.e1" e2="DDI-PubMed.25047407.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25047407.s7.e1" e2="DDI-PubMed.25047407.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25047407.s7.e2" e2="DDI-PubMed.25047407.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25047407.s7.e2" e2="DDI-PubMed.25047407.s7.e3" /></sentence><sentence text=" Safety and tolerability were assessed" /><sentence text="" /><sentence text="Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52"><entity charOffset="21-32" id="DDI-PubMed.25047407.s10.e0" text="ziprasidone" /><entity charOffset="103-114" id="DDI-PubMed.25047407.s10.e1" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.25047407.s10.e0" e2="DDI-PubMed.25047407.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25047407.s10.e0" e2="DDI-PubMed.25047407.s10.e1" /></sentence><sentence text="1 vs 50" /><sentence text="4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544" /><sentence text="6 vs 469" /><sentence text="1 ng·h/mL)" /><sentence text=" Geometric mean ratios of systemic exposure (ziprasidone alone: ziprasidone after pretreatment with armodafinil) were close to unity, with associated 90 % confidence intervals (CIs) within the range of 0"><entity charOffset="45-56" id="DDI-PubMed.25047407.s15.e0" text="ziprasidone" /><entity charOffset="64-75" id="DDI-PubMed.25047407.s15.e1" text="ziprasidone" /><entity charOffset="100-111" id="DDI-PubMed.25047407.s15.e2" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.25047407.s15.e0" e2="DDI-PubMed.25047407.s15.e0" /><pair ddi="false" e1="DDI-PubMed.25047407.s15.e0" e2="DDI-PubMed.25047407.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25047407.s15.e0" e2="DDI-PubMed.25047407.s15.e2" /><pair ddi="false" e1="DDI-PubMed.25047407.s15.e1" e2="DDI-PubMed.25047407.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25047407.s15.e1" e2="DDI-PubMed.25047407.s15.e2" /></sentence><sentence text="80-1" /><sentence text="25 (C max, 0" /><sentence text="97; 90 % CI, 0" /><sentence text="87-1" /><sentence text="08; AUC0-∞, 0" /><sentence text="86; 90 % CI, 0"><entity charOffset="9-11" id="DDI-PubMed.25047407.s21.e0" text="CI" /></sentence><sentence text="82-0" /><sentence text="91)" /><sentence text=" Adverse events were consistent with the known safety profiles of each agent" /><sentence text="" /><sentence text="Systemic exposure to ziprasidone was not affected by pretreatment with armodafinil"><entity charOffset="21-32" id="DDI-PubMed.25047407.s26.e0" text="ziprasidone" /><entity charOffset="71-82" id="DDI-PubMed.25047407.s26.e1" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.25047407.s26.e0" e2="DDI-PubMed.25047407.s26.e0" /><pair ddi="false" e1="DDI-PubMed.25047407.s26.e0" e2="DDI-PubMed.25047407.s26.e1" /></sentence><sentence text=" Both drugs were generally safe and well tolerated under the conditions studied" /><sentence text="" /></document>